How M.D. was paid
$35.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Pravin U. Dugel, M.D.Executive Chair, President and Chief Executive Officer | $819,200 | $890,880 | $18,608,000 | $15,567,000 | $61,878 | $35,946,958 |
| Donald NotmanChief Operating Officer and Chief Financial Officer | $560,175 | $406,127 | $855,600 | $1,846,179 | $2,878 | $3,670,959 |
| Nadia Waheed, M.D.Chief Medical Officer | $536,667 | $398,750 | $1,091,490 | $2,351,640 | $4,378,925 | $4,378,925 |
| Sanjay Nayak, M.B.B.S., Ph.D.Chief Strategy Officer | $510,000 | $332,775 | $825,840 | $1,791,912 | $2,878 | $3,463,405 |
| Steve MeyersChief Commercial Officer | $510,000 | $295,800 | $550,560 | $1,191,031 | $2,878 | $2,550,269 |
What changed and why
- $35.9MDr. Dugel total compensation reached $35,946,958 in fiscal 2025 following special equity grants.
- No portion of the CEO performance-based stock option or stock units had been earned by year-end 2025.
- The CEO received no equity awards at the end of 2025 or early 2026.
- 74.9%Stockholders supported the prior say-on-pay proposal with 74.9 percent of votes cast.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.